For example, the CVD-REAL-3 study was a multinational observational cohort study in patients with T2D, which compared outcomes in patients initiating SGLT2 inhibitors with those receiving other glucose-lowering drugs (47). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.